 |
(3E,5E)-3,5-bis[(4-fluoro-3-nitrophenyl)methylidene]-1-(prop-2-enoyl)azepan-4-0ne |
|---|---|
| Trade Name | |
| Orphan Indication | Multiple myeloma |
| USA Market Approval | USA |
| USA Designation Date | 2014-04-30 00:00:00 |
| Sponsor | VivoLux AB;Uppsala Science Park, SE-751 83 Uppsala; |
Related Access Program
AbbVie – Multiple Myeloma
Janssen Research & Development, LLC – Multiple Myeloma
Dana-Farber Cancer Institute – Multiple Myeloma
Bristol-Myers Squibb – Multiple Myeloma
Peking University – Multiple Myeloma
Novartis Pharmaceuticals – Multiple Myeloma
Onyx Pharmaceuticals, Inc., an Amgen subsidiary – Multiple myeloma